Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Le Coudray Cedex, France Clinical Trials

A listing of Le Coudray Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.

Phase

0.0 miles

Learn More »

Prospective Multicentric Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate Cyclophosphamide) in Large Granular Lymphocytes Leukemia

Large Granular Lymphocyte (LGL) leukemia is a clonal disorder involving tissue invasion of marrow, spleen and liver. Clinical presentation is dominated by recurrent infections associated with neutropenia, anemia, splenomegaly, and auto-immune diseases, particularly rheumatoid arthritis. Both T cell and NK cell subtypes of LGL leukemia are indolent disease and considered ...

Phase

1.56 miles

Learn More »

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients

Screening phase: New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic plateforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing). Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions ...

Phase

1.66 miles

Learn More »

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC). However, the MSI CRC representing approximately 15% of the CRCs exhibits a high mutational load which generates many potentially immunogenic neoantigens. In addition, strong expression ...

Phase

1.66 miles

Learn More »